Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2010-06-01
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07728015
ABSTRACT:
Pharmaceutical compositions are disclosed comprising betahistine, or a salt thereof, and olanzapine in amounts effective to reduce the weight gain associated with olanzapine administration.
REFERENCES:
patent: 4159332 (1979-06-01), Bollenbacher
patent: 6620942 (2003-09-01), Yeh et al.
patent: 2003/0162824 (2003-08-01), Krul
patent: 2006/0073217 (2006-04-01), Barak
patent: 2008/0003306 (2008-01-01), Barak
patent: 2008/0004254 (2008-01-01), Barak
patent: 2008/0004322 (2008-01-01), Barak
patent: 2008/0004324 (2008-01-01), Barak
patent: 2008/0051439 (2008-02-01), Barak
patent: 2008/0051440 (2008-02-01), Barak
patent: WO 00/38725 (2000-07-01), None
patent: WO 00/53162 (2000-09-01), None
patent: WO 02/087556 (2002-11-01), None
patent: WO 2004/024094 (2004-03-01), None
Gheorghiu et al., Am. J. Psychiatry, 156:11 (Nov. 1999), p. 1836.
Rossi et al., Physiology & Behavior, 66(3), pp. 517-521 (1999).
Leak et al., “Patients on Atypical Antipsychotic Drugs: Another High-Risk Groupfor Type 2 Diabetes”, Diabetes Care, 26(11): 3202-3203, 2003.
Garrow, “Does Cimetidine Cause Weight Loss?”, British Medical Journal, 306: 1084, 1994.
Rasmussen et al. “Cimetidine Suspension as Adjuvant to Energy Restricted Diet in Treating Obesity”, British Medical Journal, 306: 1093-1096,1993.
Stoe-Birketvedt “Effect of Cimetidine Suspension on Appetite and Weight in Overweight Subjects”, British Medical Journal, 306: 1091-1093, 1993.
Merck “Obesity”, The Merck Manual of Diagnosis and Therapy, 17th Ed., p. 58-60, 1999.
Ito et al. “Toxicological and Teratological Studies on N-Methyl-N-β-(2-Pyridyl)-Ethylamine (Betahistine)”, Oyo Yakuri, 2(4): 344-348, 1968.
Fossati et al. “Binding Affinity Profile of Betahistine and Its Metabolites for Central Histamine Receptors of Rodents”, Pharmacological Research, 43(4): 389-392, 2001.
Malmlöf et al. “Influence of a Selective Histamine H3 Receptor Antagonist on Hypothalamic Neural Activity, Food Intake and Body Weight”, International Journal of Obesity, p. 1-11, 2005.
Itoh et al. “Thioperamide, A Histamine H3 Receptor Antagonist, Powerfully Suppresses Peptide YY-Induced Food Intake in Rats”, Biological Psychiatry, 45: 475-481, 1999.
Hagan “Peptide YY: A Key Mediator of Orexigenic Behavior”, Peptides, 23: 377-382, 2002.
Poyurovsky et al. “The Effect of Betahistine, A Histamine H1 Receptor Antagonist/H3 Antagonist, on Olanzapine-Induce Weight Gain in First-Episode Schizophrenia Patients”, International Clinical Psychopharmacology, 20: 101-103, 2005.
Kasaoka et al. “Histidine Supplementation Suppresses Food Intake and Fat Accumulation in Rats”, Nutrition, 20: 991-996, 2004.
Baptista et al. “Drug Induced Weight Gain, An Impediment to Successful Pharmacotherapy: Focus on Antipsychotics”, Current Drug Targets, 5: 279-299, 2004.
Kane et al. “Metabolic Effects of Treatment With Atypical Antipsychotics”, Journal of Clinical Psychiatry, 65(11): 1447-1455, 2004.
Lieberman III “Metabolic Changes Associated With Antipsychotic Use”, Primary Care Companion—Journal of Clinical Psychiatry, 6(Suppl.2): 8-13, 2004.
Newcomer “Second-Generation (Atypical) Antipsychotics and Metabolic Effects”, CNS Drugs, 19(Suppl.1): 1-93, 2005.
Lecklin et al. “Inhibition of Histamine Catabolism Suppresses Fat Intake But Not the Intake of Carbohydrates and Protein”, Inflammation Research, 51(Suppl.1): S53-S54, 2002.
Rasmussen et al. “Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-Methozyethyl)-4-Methyl-Piperazin-1-Y1]-2-Methyl-4H-3-Thia-4,9-Diaza-Benzo[f]Azulene]: A Potential Novel Antipsychotic With Lower Histamine H1 Receptor Affinity Than Olanzapine”, The Journal of Pharmacology and Experimental Therapeutics, 315(3): 1265-1277, 2005.
Wetterling “Bodyweight Gain with Atypical Antipsychotics”, Drug Safety, 24(1): 59-73, 2001.
Orthen-Gambill “Antihistaminic Drugs Increase Feeding, While Histidine Suppresses Fedding in Rats”, Pharmacology Biochemistry & Behavior, 31: 81-86, 1988.
Sakata et al. “Blockade of the histamine Hi-receptor in the rat ventromedial hypothalamus and feeding elicitation”,Brain Research, 441: 403-407, 1988.
Wirshing et al. “Novel Antipsychotics: Comparison of Weight Gain Liabilities”, Journal of Clinical Psychiatry 60(6): 358-363, 1999.
Wirshing et al. “Schizophrenia and Obesity: Impact of Antipsychotic Medications”, Journal of Cliinical Psychiatry, 65(18): 13-26, 2004.
Lecklin et al. “Effects of Intracerebroventricularly Infused Histamine and Selective H1H 2 and H3Agonists on Food and Water Intake and Urine Flow in Wistar Rats 3”, Brain Research, 793: 279-288, 1998.
Masaki et al. “The Hypothalamic H1 Receptor: a Novel Therapeutic Target for Disrupting Diurnal feeding Rhythm and obesity”, TRENDS in Pharmacological Sciences,.27 (.5):279-285.
Masaki et al. “Central Infusion of Histamine Reduces Fat Accumulation and Upregulates UCP Family in Leptin-Resistant Obese Mice”, Diabetes, 50: 379-384, 2001.
Yoshimatsu et al. “Histamine Neurons Down-Regulate ob Gene Expression in Rat White Adipose Tissue”, Inflamm. res. 50, (Suppl 2): S72-S73, 2001.
Masaki et al. “Involvement of Hypothalamic Histamine H1 Receptor in the Regulation of Feeding Rhythm and Obesity”, Diabetes, 53, 2250-2260, 2004.
Rossi et al. “Effect of the H1-Histamine Receptor Agonist Betahistine on Drinking and Eating Behavior in Pygmy Goats” Physiology & Behavior, vol. 66, No. 3, pp. 517-521, 1999.
Szelag et al. “Betahistine Inhibits food Intake in Rats”, Polish Journal of Pharmacology, Pol. J. Pharmacol., 2001, 53:701-707.
Abramof Ness et al. “Drug-Induced Weight Gain”, Drugs of Today, 41, 2005.
Navarro-Badenes et al. “Weight gain associated with cinnarizine”, Ann Pharmacother. 26(7-8):928-30. Jul.-Aug. 1992. Abstract.
Albera et al. “Double-Blind, Randomized, Multicenter Study Comparing the Effect of Betahistine and Flunarizine on the Dizziness Handicap in Patients With Recurrent Vestibular Vertigo”, Acta Otalaryngol, 123: 588-593, 2003.
Arrang et al. “Actions of Betahistine at Histamine Receptors in the Brain”, European Journal of Pharmacology, 111: 73-84, 1985.
Attoub et al. “The H3 Receptor Is Involved in Cholecystokinin Inhibition of Food Intake in Rats”, Life Sciences, 69: 469-478, 2001.
Barbarich et al. “An Open Trial of Olanzapine in Anorexia Nervosa”, Journal of Clinical Psychiatry, 65(11): 1480-1482, 2004.
Barrett et al. “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes”, Journal of Clinical Psychiatry, 65(2): 267-272, 2004.
Bjenning et al. “OCFR and CFR (6-33) Depress Food But Not Water Intake in the Obese Zucker Rat”, International Journal of Obesity, 24(Suppl.2):S140-S141, 2000.
Bustillo et al. “Differential Effect of Clozapine on Weight: A Controlled Study”, The American Journal of Psychiatry, 153(6): 817-819, 1996.
Gordon et al. “Evaluation of Betahistine for the Prevention of Seasickness: Effect on Vestibular Function, Psychomotor Performance and Efficacy at Sea”, Journal of Vestibular Research, 13: 103-111, 2003.
Onderwater et al. “Cytotoxicity of a Series of Mono- and Di-Substituted Thiourea in Freshly Isolated Rat Hepatocytes: A Preliminary Structure-Toxicity Relationship Study”, Toxicology, 125: 117-129, 1998.
Sakata et al. “Hypothalamic Neuronal Histamine: Implications of Its Homeostatic Control of Energy Metabolism”, Nutrition, 13: 403-411, 1997.
Seifert et al. “Multiple Differences in Agonist and Antagonist Pharmacology Between Human and Guinea Pig Histmaine H1-Receptor”, The Journal of Pharmacology and Experimental Therapeutics, 305(3): 1104-1115, 2003.
Se
Mor Research Applications Ltd.
Spivack Phyllis G.
LandOfFree
Compositions for weight management does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for weight management, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for weight management will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206652